Redcliffe Lifetech
-7%
est. 2Y upside i
Redcliffe Labs is India's Largest Omni-channel Diagnostics platform
Rank
#2461
Sector
Healthcare Diagnostics
Est. Liquidity
~4Y
Data Quality
Data: MediumRedcliffe offers a negative expected return of -7% over 2 years, weighed down by a stale valuation, low growth, and high preference stack risk.
Last updated: July 19, 2026
If Redcliffe achieves a 6x exit multiple on ~$79M revenue, driven by an IPO window or category leadership, employee common stock returns ~56% after 20% dilution.
With a 4x exit multiple (converging to public comps), the base case return is near zero (-2.6%) factoring 20% dilution from expected future funding.
If multiple compresses to 2.5x due to competitive pressure and slowing growth, common stock loses ~47% after dilution, though exit value stays above the $116M preference stack.
Preference Stack Risk
severeFunding Intensity
4290%Total funding of $116M represents 43% of the $270M entry valuation, creating a 1x liquidation preference overhang.
Dilution Risk
highGiven cash burn and last round 22 months ago, a follow-on round within 24 months is likely, diluting common shares by ~20%.
Secondary Liquidity
noneNo secondary market activity observed; equity is illiquid until an exit.
Questions to Ask at the Interview
Strategic questions based on Redcliffe Lifetech's data — designed to show you've done your homework.
- 1
“How does Redcliffe's unit economics compare to Thyrocare's?”
- 2
“What is the path to profitability given current burn rate and growth?”
- 3
“How does the preference stack affect employee equity value in a down round?”
Community
Valuation Sentiment
Our model estimates -7% upside. What do you think?
Anonymous. Do not share material non-public information.
Community Discussion
Comments are reviewed before they appear publicly.
Loading comments...
Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.